



**PROPOSAL FOR REVISION:**

**GOOD MANUFACTURING PRACTICES (GMP) FOR  
ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)**

On the basis of a recommendation from the informal WHO consultation on new approaches and risk evaluation for manufacture of medicines, held in Geneva on 30 May-1 June 2007, we should be grateful to receive your feedback/comments as to whether you consider it appropriate for WHO to revise its current good manufacturing practices (GMP) for active pharmaceutical ingredients (APIs) (WHO good manufacturing practices: starting materials. In: *Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2, 2<sup>nd</sup> updated edition*. Geneva, World Health Organization, 2007, p. 188: [http://www.who.int/medicines/areas/quality\\_safety/quality\\_assurance/production/en/index.html](http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html)) with the principles laid out in the ICH GMP guide for APIs (<http://www.ich.org/cache/compo/276-254-1.html>).

Please send any comments you may have on this proposal to Dr S. Kopp, Quality Assurance Programme: [kopps@who.int](mailto:kopps@who.int) with a copy to [locontea@who.int](mailto:locontea@who.int) or fax: (41-22) 791 4730 by 30 November 2007. In the meantime this proposal will be discussed during the next meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.

---

© World Health Organization 2007

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of WHO. The draft should not be displayed on any web site.

Please send any request for permission to:

Dr S. Kopp, Quality Assurance & Safety: Medicines (QSM), Department of Medicines Policy and Standards (PSM), World Health Organization, CH-1211 Geneva 27, Switzerland; Fax: (41-22) 791 4730; e-mail: [kopps@who.int](mailto:kopps@who.int)

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this draft is complete and correct and shall not be liable for any damages incurred as a result of its use.

**SCHEDULE FOR THE PROPOSED ADOPTION PROCESS OF DOCUMENT QAS/07.239:**

***PROPOSAL FOR REVISION:***

***WHO GOOD MANUFACTURING PRACTICES (GMP) FOR ACTIVE PHARMACEUTICAL  
INGREDIENTS (APIs)***

Discussion during consultation on new approaches and risk evaluation for manufacture of medicines	30 May-1 June 2007
Mailing of proposal for revision for comments	October 2007
Presentation to WHO Expert Committee on Specifications for Pharmaceutical Preparations	15-19 October 2007
Follow-up action as required	October 2007 - ...
Collation of comments	October-November 2007

***PROPOSAL FOR REVISION:  
WHO GOOD MANUFACTURING PRACTICES (GMP) FOR ACTIVE PHARMACEUTICAL  
INGREDIENTS (APIs)***

Discussions were held at an informal WHO consultation on new approaches and risk evaluation for manufacture of medicines in Geneva on 30 May-1 June 2007 as to whether the current WHO good manufacturing practices (GMP) for active pharmaceutical ingredients (APIs) should be revised to bring them into line with the ICH GMP guide for APIs (reference ICH Q7A).

Both texts can be found at the following web links:

- WHO good manufacturing practices (GMP) for active pharmaceutical ingredients (APIs). In: WHO good manufacturing practices: starting materials. In: *Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2, 2<sup>nd</sup> updated edition*. Geneva, World Health Organization, 2007, p. 188: [http://www.who.int/medicines/areas/quality\\_safety/quality\\_assurance/production/en/index.html](http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html)
- ICH GMP guide for APIs (ICH Q7A): <http://www.ich.org/cache/compo/276-254-1.html>.

In this respect a stepwise approach should be considered, including different scenarios.

It was recommended that the ICH Q7A guide should be adopted because:

- it has been adopted by numerous regulatory authorities worldwide;
- use of the guide has shown it has been well written; and
- many API manufacturers already comply with ICH guidelines.

The World Health Organization develops global guidelines, for which it must work through its own processes with confirmation by the WHO Legal Counsel.

During the above-mentioned consultation various approaches used in different countries were presented, e.g.

- Brazil: implements ICH Q7A, first listing of manufacturers followed by inspection;
- China: licensing of API manufacturers, revision of GMP is under way, and selected

- items of ICH Q7A will be adopted for the parts not included in the main GMP text.  
Finalization is expected end 2007;
- India: APIs mostly produced for exports, and compliance with Schedule M (since 2005), with no change for API GMP requirements.

## **PROPOSED ACTIONS**

1. Replace the current WHO GMP guide for APIs by the principles of ICH Q7A.
2. If the new approach as in 1. above is adopted a stepwise approach towards new GMP conditions is proposed.

The implementation phase might take time and a transition phase would be necessary.

\*\*\*

Draft for comment